Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Haisco In-Licenses Oral Film Version of Riluzole for ALS

publication date: Mar 3, 2022

Haisco Pharma in-licensed China rights to Exservan™ , an oral film formulation of riluzole for patients with amyotrophic lateral sclerosis, from Aquestive Therapeutics of New Jersey. Riluzole is a disease-modifying therapy for ALS, but patients often become unable to swallow a pill. The oral film allows them to continue therapy. Haisco will make a $7 million upfront payment and be responsible for regulatory and commercialization of Exservan in China. It will also pay milestones and double-digit royalties on sales. Haisco, a Chengdu company, offers specialized medical products to China patients. More details....

Stock Symbols: (SHZ: 002653) (NSDQ: AQST)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here